Emcure Pharmaceuticals has received approval from the Central Drugs Standard Control Organisation (CDSCO) to market Poviztra for treating fatty liver disease in adults. The approval allows the company to introduce the drug for metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease linked to metabolic disorders.
Poviztra Uses Semaglutide for MASH Treatment
Poviztra contains semaglutide, a GLP-1 receptor agonist that was originally developed for weight management. With the latest regulatory clearance, the drug can now support the treatment of adults with MASH, along with lifestyle changes such as a reduced-calorie diet and increased physical activity.
Approval Follows Wegovy’s Regulatory Milestone
As per Medical Dialogues, the CDSCO’s approval of Novo Nordisk’s Wegovy for fatty liver disease paved the way for expanding semaglutide-based treatments in India. Following this development, Emcure’s Poviztra received approval for the same therapeutic area, improving access to treatment options for patients with metabolic liver conditions.
A Step Forward in Fatty Liver Management
MASH can progress over time and may lead to serious liver complications if left unmanaged. Therefore, the availability of semaglutide-based therapies marks an important development in addressing fatty liver disease, especially among patients with obesity and metabolic risk factors.
Emcure Expands Its Metabolic Health Portfolio
With the approval of Poviztra, Emcure strengthens its presence in the growing metabolic health segment. The company can now offer an additional treatment option as healthcare providers look for effective therapies to manage obesity-related and liver-related conditions.